Hepatitis B virus (HBV) belongs to family
Hepadnaviridae and is a DNA virus. HBV causes acute and chronic liver disease. Although HBV vaccine is currently used, HBV infection remains one of the 10 most common causes of the death worldwide. About 400 million of the world population is infected with HBV, and around 250,000 people die each year from HBV related liver disease such as cirrhosis and hepatocellular carcinoma (
1). A high prevalence of HBV infection was reported in Iran (
2).
Healthcare workers are exposed to blood and body fluids. They are also at risk of incidents like needle stick, sharp injuries, and the like that could make the transmission of HBV infection easy through health care workers (
3). The risk of acquiring hepatitis B infection among the health care workers is about 10 times higher than other groups (
4). The HBs antibody has an important role in the protection against HBV infection (
5). The expression of antiviral, Th1 cytokines such as gamma interferon (IFN-γ) and tumor necrosis factor-α (TNF-α) can control hepatitis B infection (
6). Hepatitis B vaccine can motivate the immune system to produce both HBsAb and specific HBs gamma interferon (
7). Immunization with hepatitis B vaccine at first day, 30th day, and 180th day can create 90% and 95% protection in adults and children, respectively (
8). Antibody protection for general population is found at the titer of > 10 mIU/mL (
9,
10). Persons with anti-HBs titer < 10 mIU/mL are defined as non-responder, and persons with anti-HBs titer > 10 and < 99 mIU/mL are defined as hyporesponders. They usually show shorter period of detectable antibody called “waning antibody” or “waning immunity” (
11,
12).